Tag Archives: Gilead

Supreme Court rebuffs appeals from Merck, Gilead in 2 high-profile drug battles

Monday was a good-news-bad-news day for Gilead Sciences at the U.S. Supreme Court, with the justices handing down multiple decisions about which appeals they would take up as they headed back to work after the holiday break. SCOTUS refused to hear Gilead’s appeal in a whistleblower case alleging it lied to the FDA about unapproved… Read More »

ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah

SAN DIEGO—Gilead and Novartis are working to ramp up launches of their slow-starting CAR-T drugs, and both companies are hoping longer-term follow-up data will help do the trick. Sunday at the American Society of Hematology (ASH) annual meeting, Gilead’s Kite unit rolled out two-year data from the Zuma-1 study that won Yescarta its October 2017 approval… Read More »